Triple-costimulatory GD2-CAR T cells incorporating CD28, 4–1BB and CD27 mediate potent cytotoxicity and reduce exhaustion in solid tumour models

Disialoganglioside (GD2) is a validated tumour-associated antigen for chimeric antigen receptor (CAR) T-cell therapy; yet most GD2-CAR constructs carry limited costimulatory signaling, which may constrain efficacy and durability. We engineered humanised hu3F8-based GD2-CAR T cells bearing dual or triple costimulatory domains- GD2-28BBζ (CD28/4-1BB), GD2-28.27ζ (CD28/CD27) and GD2-28BB27ζ (CD28/4-1BB/CD27) - and compared their in-vitro function against GD2-positive neuroblastoma (SK-N-AS), lung adenocarcinoma (A549) and retinoblastoma (Y79 and WERI-Rb-1) cells. All three mediated antigen-specific cytotoxicity against GD2-positive lines while sparing GD2-negative targets. At the lowest effector-to-target ratio, GD2-28BB27ζ T cells retained significantly killing of SK-N-AS cells where the third-generation constructs did not, indicating potent cytotoxicity under limiting effector conditions, whereas GD2-28.27ζ T cells showed the greatest proliferation, reaching significance against WERI-Rb-1. On antigen engagement, GD2-28BB27ζ T cells sustained cytotoxicity while secreting less IL-2, IFN-γ and TNF-α than the other constructs, indicating an uncoupling of lytic function from effector-cytokine output. Under serial tumour rechallenge, GD2-28BB27ζ T cells maintained cytolytic function, acquired fewer activation and exhaustion markers (CD69, TIM-3 and, versus GD2-28BBζ, LAG-3; PD-1 unchanged), better preserved their CAR⁺ population, and retained a larger naïve-like (CD45RO⁻CD62L⁺) subset than the other constructs. Together, these in-vitro findings indicate that combining CD28, 4-1BB and CD27 within a single CAR confers potent cytotoxicity with low effector-to-target ratios, lower effector-cytokine output, reduced exhaustion-marker acquisition and greater phenotypic durability, identifying GD2-28BB27ζ as a promising configuration for GD2-positive tumours that warrants in vivo evaluation.

Authors

Institutions

Publication Details

Journal
Biomedicine & Pharmacotherapy
Published
2026-09-01
DOI
https://doi.org/10.1016/j.biopha.2026.119897
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Triple-costimulatory GD2-CAR T cells incorporating CD28, 4–1BB and CD27 mediate potent cytotoxicity and reduce exhaustion in solid tumour models

Jatuporn Sujjitjoon, Pa‐thai Yenchitsomanus, Pornpimon Yuti, Naravat Poungvarin et al.
Biomedicine & Pharmacotherapy
CAR-T cell therapy research
article

Triple-costimulatory GD2-CAR T cells incorporating CD28, 4–1BB and CD27 mediate potent cytotoxicity and reduce exhaustion in solid tumour models

Jatuporn Sujjitjoon, Pa‐thai Yenchitsomanus, Pornpimon Yuti, Naravat Poungvarin, K. Kongkla, Nunghathai Sawasdee, Krissada Natungnuy
article en

Abstract

Disialoganglioside (GD2) is a validated tumour-associated antigen for chimeric antigen receptor (CAR) T-cell therapy; yet most GD2-CAR constructs carry limited costimulatory signaling, which may constrain efficacy and durability. We engineered humanised hu3F8-based GD2-CAR T cells bearing dual or triple costimulatory domains- GD2-28BBζ (CD28/4-1BB), GD2-28.27ζ (CD28/CD27) and GD2-28BB27ζ (CD28/4-1BB/CD27) - and compared their in-vitro function against GD2-positive neuroblastoma (SK-N-AS), lung adenocarcinoma (A549) and retinoblastoma (Y79 and WERI-Rb-1) cells. All three mediated antigen-specific cytotoxicity against GD2-positive lines while sparing GD2-negative targets. At the lowest effector-to-target ratio, GD2-28BB27ζ T cells retained significantly killing of SK-N-AS cells where the third-generation constructs did not, indicating potent cytotoxicity under limiting effector conditions, whereas GD2-28.27ζ T cells showed the greatest proliferation, reaching significance against WERI-Rb-1. On antigen engagement, GD2-28BB27ζ T cells sustained cytotoxicity while secreting less IL-2, IFN-γ and TNF-α than the other constructs, indicating an uncoupling of lytic function from effector-cytokine output. Under serial tumour rechallenge, GD2-28BB27ζ T cells maintained cytolytic function, acquired fewer activation and exhaustion markers (CD69, TIM-3 and, versus GD2-28BBζ, LAG-3; PD-1 unchanged), better preserved their CAR⁺ population, and retained a larger naïve-like (CD45RO⁻CD62L⁺) subset than the other constructs. Together, these in-vitro findings indicate that combining CD28, 4-1BB and CD27 within a single CAR confers potent cytotoxicity with low effector-to-target ratios, lower effector-cytokine output, reduced exhaustion-marker acquisition and greater phenotypic durability, identifying GD2-28BB27ζ as a promising configuration for GD2-positive tumours that warrants in vivo evaluation.

Biomedicine & PharmacotherapyVol. 203
Siriraj Hospital (TH), Mahidol University (TH)
Mahidol University, National Research Council of Thailand, Faculty of Medicine Siriraj Hospital, Mahidol University
Openalex Percentile: Top 13%
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.